Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following two negative opinions from the European Medicines Agency (EMA) on its drug narsoplimab for treating TA-TMA. The EMA's rejection in June and again after re-examination in October caused Omeros's stock to fall significantly. The investigation aims to determine if Omeros or its executives engaged in unlawful business practices. Investors affected by these events may consider joining the class action lawsuit.
Omeros Corporation faces an investigation for potential securities fraud. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 06, 2026 07:51 WIB: out of 150 priced US health stocks, 18 rose and 132 fell. Notable movers include NTRA at USD 304.05 with a 1-day change of -22.24%, FLNA at USD 0.47 down 19.26%, and GH at USD 137.00 down 18.73%.
Ademi LLP is investigating Strategic Education for potential securities fraud related to inaccurate statements about its financials and business operations, particularly in Australia. This probe follows a more than 20% decline in the company's stock ...
Corporate Insight released research identifying top financial firms leading in customer-facing AI tools, including virtual assistants and AI-powered fintech platforms. Fidelity and Voya lead in retirement plan virtual assistants, while Lively excels ...
Strawberry Fields REIT announced a cash dividend of $0.17 per common share for the fourth quarter of 2026. The dividend will be paid on December 30, 2026, to shareholders recorded by December 16, 2026. The company specializes in owning and leasing he...
Syndax Pharmaceuticals is under investigation by Pomerantz LLP for possible securities fraud following the failure of its MAXPIRe Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis, which missed its primary endpoint. The trial news caused ...
Evolus, Inc. is under investigation by Pomerantz LLP following an FDA warning about a misleading Instagram promotion for its wrinkle treatment Jeuveau. The FDA criticized the ad for downplaying safety risks and making exaggerated claims about the pro...
